Blood pressure changes during clozapine or olanzapine treatment in Korean schizophrenic patients

World Journal of Biological Psychiatry

Volumn 10, Issue 4 PART 2, 2009, Pages 420-425

  Woo, Young Sup ^a   Kim, Won ^b   Chae, Jeong Ho ^a   Yoon, Bo Hyun ^c   Bahk, Won Myong ^a  

^a The Catholic University of Korea   (South Korea)

^b Inje University College of Medicine   (South Korea)

^c Naju National Hospital   (South Korea)

Author keywords

Blood pressure; Clozapine; Olanzapine; Schizophrenia

Indexed keywords

CLOZAPINE; OLANZAPINE; BENZODIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT;

ADULT; ARTICLE; BLOOD PRESSURE MONITORING; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; HUMAN; HYPERTENSION; KOREA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; SCHIZOPHRENIA; SYSTOLIC BLOOD PRESSURE; BLOOD PRESSURE; BODY WEIGHT; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; DRUG EFFECT; MIDDLE AGED; RETROSPECTIVE STUDY; RISK FACTOR; SOUTH KOREA;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BLOOD PRESSURE; BODY WEIGHT; CARDIOVASCULAR DISEASES; CLOZAPINE; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; RISK FACTORS; SCHIZOPHRENIA;

EID: 77449085833     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.1080/15622970801910399     Document Type: Article

References (34)

1. Allison DB, Casey DE. 2001. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry 62(Suppl 7):22-31.
2. Baldessarini RJ, Frankenburg FR. 1991. Clozapine: a novel antipsychotic agent. New Engl J Med 324:746-754.
3. Beasley CM Jr, Tollefson GD, Tran PV. 1997. Safety of olanzapine. J Clin Psychiatry 58(Suppl 10):13-17.
4. Benotti PN, Bistrian B, Benotti JR, Blackburn G, Forse RA. 1992. Heart disease and hypertension in severe obesity. The benefist of weight reduction. Am J Clin Nutr 55(Suppl 2):586-590S.
5. Casey DE. 1997. The relationship of pharmacology to side effects. J Clin Psychiatry 58(Suppl 10):55-62.
6. Chobanian AV, Bakris GL, Black HR. 2003. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. J Am Med Assoc 289:2560-2572.
7. Cohen H, Loewenthal U, Matar M, Kotler M. 2001. Association of autonomic dysfunction and clozapine. Br J Psychiatry 179:167-171.
8. Conley RR, Meltzer HY. 2000. Adverse events related to olanzapine. J Clin Psychiatry 61(Suppl 8):26-29.
9. Davidson M. 2002. Risk of cardiovascular disease and sudden death in schizophrenia. J Clin Psychiatry 63(Suppl 9):5-11.
10. Dawber TR, Meadors GF, Moore FE. 1951. Epidemiological approaches to heart disease: the Framingham Study. Am J Public Health 41:279-286.
11. Ereshefsky L, Watanabe MD, Tran-Johnson TK. 1989. Clozapine: an atypical antipsychotic agent. Clin Pharm 8:691-709.
12. Fontaine KR, Heo M, Harrigan EP, et al. 2001. Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate. Psychiatry Res 101:277-288.
13. George TP, Winther LC. 1996. Hypertension after initiation of clozapine [letter]. Am J Psychiatry 153:1368-1369.
14. Gupta S, Rajaprabhakaran R. 1994. Paradoxical hypertension associated with clozapine [letter]. Am J Psychiatry 151:148.
15. Harris EC, Barraclough B. 1998. Excess mortality of mental disorder. Br J Psychiatry 173:11-53.
16. Haupt DW. 2006. Differential metabolic effects of antipsychotic treatments. Eur Neuropsychopharmacol 16(Suppl 3):s149-155.
17. Henderson DC, Daley TB, Kunkel L, Rodrigues-Scott M, Koul P, Hayden D. 2004. Clozapine and hypertension: A chart review of 82 patients. J Clin Psychiatry 65:686-689.
18. Hennekens CH, Hennekens AR, Hollar D, Casey DE. 2005. Schizophrenia and increased risks of cardiovascualr disease. Am Heart J 150:1115-1121.
19. Kane J, Honigfeld G, Singer J, Meltzer H. 1988. Clozapine for the treatment-resistant schizophrenia: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45:789-796.
20. Lambert B, Tafesse E, Carson WH Jr. 2003. Antipsychotic-induced hyperlipidemia among people with schizophrenia. Presented at the 156th annual meeting of the American Psychiatric Association; San Fransisco, CA.
21. Liebermann JA, Kane JM, Johns CA. 2001. Clozapine: guidelines for clinical management. J Clin Psychiatry 62(Suppl 7):22-31.
22. Littrell K, Johnson CG, Hilligoss NM, Peabody CD, Littrell SH. 2000. Switching clozapine responders to olanzapine. J Clin Psychiatry 61:912-915.
23. Lund BC, Perry PJ, Brooks JM, Arndt S. 2001. Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: a claims-based approach. Arch Gen Psychiatry 58:1172-1176.
24. Meltzer HY. 1995. Atypical antipsychotic drugs. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: The fourth generation of progress. New York: Raven Press. p 1277-1286.
25. Mokdad AH, Marks JS, Stroup DF, Gerberding JL. 2004. Actual causes of death in the United States, 2000. J Am Med Assoc 291:1238-1245.
26. Mueck-Weymann M, Acker J, Agelink MW. 2001. Autonomic responses of blood vessels and sweat glands in patients with schizophrenia treated with olanzapine or clozapine. Psycho-pharmacology 154:368-372.
27. Naber D, Hippius H. 1990. The European experience with clozapine. Hosp Comm Psychiatry 41:886-890.
28. Nemeroff CB. 1997. Dosing the antipsychotic medication olanzapine. J Clin Psychiatry 58:45-49.
29. Povlsen UJ, Noring U, Fog R, Gerlach J. 1985. Tolerability and therapeutic effect of clozapine: a retrospective investigation of 216 patients treated with clozapine for up to 12 years. Acta Psychiatr Scand 71:176-185.
30. Richelson E, Souder T 2000. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci 68:29-39.
31. Russell JM, Mackell JA. 2001. Bodyweight gain associated with atypical antipsychotics: epidemiology and therapeutic implications. CNS Drugs 15:537-551.
32. Ryan MC, Thakore JH. 2002. Physical consequences of schizophrenia and its treatment: the metabolic syndrome. Life Sci 71:239-257.
33. Sachs GS, Guille C. 1999. Weight gain associated with use of psychotropic medications. J Clin Psychiatry 60(Suppl 21): 16-19.
34. Stamler R, Stamler J, Riedlinger WF, Algera G, Roberts RH. 1978. Weight and blood pressure. Findings in hypertension screening of 1 million Americans. J Am Med Assoc 240: 1607-1610.